Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

AffyXell Successfully Completes Funding Round

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Avacta Group plc (AIM: AVCT), a clinical-stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, today announces that AffyXell, its joint venture with Daewoong Pharmaceuticals Co., Ltd., a publicly listed South Korean pharmaceutical company, has successfully completed a funding round to advance its lead mesenchymal stem cell (MSC) program towards the clinic and to develop its wider pre-clinical pipeline of cell therapies.

AffyXell is a joint venture established in January 2020 by Daewoong Pharmaceuticals and Avacta, developing the next generation of cell and gene therapies based on mesenchymal stem cells which incorporate Affimer® immunotherapies. This new class of stem cell therapy is designed to produce Affimer® proteins, in situ in the body, that reduce inflammatory or autoimmune responses to the stem cell therapy to potentially enhance their therapeutic effects.

The proceeds of the fundraise, which remain undisclosed for reasons of confidentiality, from existing and new financial and strategic investors, will allow the company to progress through significant value inflection points. The funds will be used to support Investigational New Drug (IND) enabling studies that will underpin a regulatory filing to take its lead program into the clinic. The funding will also allow AffyXell to develop a broader pipeline of cell therapies to address a wide range of immune diseases with high unmet needs and to reinforce its platform IP portfolio.

Dr Alastair Smith, Chief Executive of Avacta Group plc commented:

“We are delighted with the continued strong progress made by AffyXell. This joint venture with Daewoong Pharmaceutical is a key strategic collaboration allowing us to demonstrate the potential of the Affimer platform to enhance cell therapies generally, as well as providing an opportunity to address high unmet need in AffyXell’s focus area of immune diseases.”

Dr Jong Sang Ryu, Chief Executive Officer of AffyXell said:

“I am very pleased that we have raised the capital required to accelerate the development of therapies using AFX platform targeting intractable diseases and providing meaningful options for suffering patients, especially in the immunology area.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine